Source: Japan’s Takeda Pharmaceutical is about to become a major international player on the biopharma scene, with its purchase of larger Irish rival Shire (SHPG, +1.41%). It’s one of the biggest pharma deals in history, and the largest-ever international takeover by any Japanese company, at a value of $62 billion.…...
Encore Dermatology Inc. Announces the Launch of IMPOYZ (clobetasol propionate) Cream, 0.025%, a Newly Formulated High-Potency Topical Corticosteroid
Source: Business Wire MALVERN, Pa.--(BUSINESS WIRE)--Encore Dermatology Inc. announces today the availability of a new topical product, IMPOYZ Cream, indicated for the treatment of moderate to severe plaque psoriasis in patients 18 years of age or older. IMPOYZ Cream is the only FDA-approved high-potency topical corticosteroid with 0.025% clobetasol propionate.…...
Datavant Acquires Universal Patient Key and Closes $40M Financing Round
Source: PR Newswire SAN FRANCISCO, April 30, 2018 /PRNewswire/ -- Datavant, the leader in helping healthcare organizations safely link their data to improve medical research and patient care, today announced that it has acquired Universal Patient Key (UPK), the leading provider of HIPAA-compliant de-identification services for healthcare data. UPK has…...
Sun Pharma Announces U.S. FDA Approval of ILUMYA™ (tildrakizumab-asmn) for the Treatment of Moderate-to-Severe Plaque Psoriasis
Source: "Sun Pharma" and includes its subsidiaries and/or associate companies) announced that the U.S. Food and Drug Administration (FDA) has approved ILUMYA™ (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. ILUMYA selectively binds to the p19 subunit of IL-23 and…...
Cigna to Acquire Express Scripts for $67 Billion
Source: Drives greater affordability and connectivity with customers and their health care providers, while making health care simpler Creates an expanded portfolio of health services with greater choice, alignment and value across a proven services platform Expands distribution of health services for employers, health plans and government agencies Delivers first…...
Sienna Biopharmaceuticals Announces First Patient Dosed in First-in-Human Trial of Topical SNA-125
Source: WESTLAKE VILLAGE, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that the first patient has been dosed in the Company’s first-in-human, Phase 1/2 proof-of-concept clinical trial of topical product candidate SNA-125 in the treatment of psoriasis and the associated pruritus, or itch. SNA-125 is…...
QFR Solutions Earns Another Top Spot
Source: LinkedIn QFR Solutions has earned another Top spot in LinkedIn’s Top 25 Most Socially Engaged Staffing Agencies. This is the second top spot for QFR Solutions since the inception of the awards in 2016. QFR ranked #2 in 2017 and #1 in 2016. There were nearly 30,000 firms considered…...
Celgene’s $7 Billion Purchase Is Great For Drug Inventors. Is It Great For Celgene?
Source: Forbes Last night, Celgene announced that it is buying Impact BioMedicines, a small biotech developing a drug to compete with the blockbuster blood cancer drug Jakafi, sold by Incyte and Novartis, in an announcement timed to coincide with the annual J.P. Morgan Health Care Conference, where Celgene, as it…...
Aclaris Therapeutics Receives FDA Approval for ESKATA™ (Hydrogen Peroxide) Topical Solution, 40% (w/w) for the Treatment of Raised Seborrheic Keratoses (SKs)
Source: Aclaris Therapeutics MALVERN, Pa., Dec. 15, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved ESKATA™ (hydrogen peroxide) topical solution, 40% (w/w) for the treatment of raised seborrheic keratoses, or SKs. SKs are non-cancerous…...
Dr. Reddy’s Announces Approval of Impoyz™ (clobetasol propionate) Cream, 0.025% First-Cycle NDA Approval
Source: Business Wire December 01, 2017 01:05 AM Eastern Standard Time HYDERABAD, India & PRINCETON, N.J. & MALVERN, Pa.-- Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), through its wholly owned subsidiary Promius Pharma, LLC, today announced its fifth consecutive, first-cycle NDA approval for the Proprietary Products Group,…...